CAS 与Obiter Research签署多年协议 向其研发团队提供SciFinder

2014-11-21 佚名 生物谷

美国俄亥俄州哥伦布市——全球化学信息权威机构美国化学文摘社(以下简称CAS)近日宣布,与著名的合同定制的化学研究和制造公司Obiter Research签署多年合作协议。根据协议,Obiter Research的研发人员将利用化学研究首选工具SciFinder?,获取最准确、最全面和最及时的化学及相关科学研究信息。 Obiter Research致力于为制药、农药和生物技术公司,以及学术机构

美国俄亥俄州哥伦布市——全球化学信息权威机构美国化学文摘社(以下简称CAS)近日宣布,与著名的合同定制的化学研究和制造公司Obiter Research签署多年合作协议。根据协议,Obiter Research的研发人员将利用化学研究首选工具SciFinder?,获取最准确、最全面和最及时的化学及相关科学研究信息。

Obiter Research致力于为制药、农药和生物技术公司,以及学术机构定制合成需多步反应才能完成的复杂化合物。即使是极复杂的工艺流程及化学合成,Obiter仍能拥有很高的成功率。现在,它正信心百倍地扩展业务,同时成立合同承包的制造分公司。

Obiter的主席兼执行化学家William Boulanger博士说到:“SciFinder?是我们最重要的工具之一。在设计合成路线时,获取一个化合物的最新信息往往是不够的。对于我们来说,最新的合成方法有时并非是最好的选择。”

William Boulanger博士还提到,他们的研究经常需要参考追溯到十九世纪的出版物。因此,对Obiter来说,获得只有SciFinder?才能提供的信息(包括历史悠久的出版物),这尤为重要。Obiter的科学家们充分利用SciFinder?中庞大的信息资源,评估合成方法、实验步骤和属性数据,并获取原文。他们通过寻找最佳合成路线节省合成成本,然后向客户提供最合适的价格,从而将这种低成本效益传递给顾客,使之受益。

Obiter也正在扩充其化学产品线,目前的产品包括医药中间体、单体及放射性核素螯合剂等。为了扩大销售,Obiter已成为CHEMCATS?(CHEMCATS是一个集全球化学商品信息为一体的重要数据库,可通过CAS的SciFinder和STN?进行访问及检索)的供应商之一,提高了Obiter产品在潜在买方中的可见度,同时也为顾客提供了方便易得的商品购买信息。

事实上,Obiter原先是SciFinder?的客户,后来改用其它检索产品,但是很快发现这些产品的缺陷,意识到它们无法满足Obiter的研究所需。

“我们非常高兴为Obiter提供他们所需的深而广的内容,帮助他们成功地为市场服务,实现业务的增长。” CAS市场营销副总裁Chris McCue说道:“Obiter Research再次选择CAS,进一步证明CAS旗下的数据库及SciFinder?所体现的无与伦比的价值。他们将SciFinder?视为业务迅速拓展的重要资源, 为此,我们深感自豪。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1299836, encodeId=bd631299836e1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469069, encodeId=93841469069a0, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506196, encodeId=124515061965b, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3491, encryptionId=f8ec34917a, topicName=BiTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557722, encodeId=2be1155e72283, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624729, encodeId=89391624e2933, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2014-11-23 lqvr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1299836, encodeId=bd631299836e1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469069, encodeId=93841469069a0, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506196, encodeId=124515061965b, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3491, encryptionId=f8ec34917a, topicName=BiTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557722, encodeId=2be1155e72283, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624729, encodeId=89391624e2933, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2014-11-23 xiaogang319
  3. [GetPortalCommentsPageByObjectIdResponse(id=1299836, encodeId=bd631299836e1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469069, encodeId=93841469069a0, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506196, encodeId=124515061965b, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3491, encryptionId=f8ec34917a, topicName=BiTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557722, encodeId=2be1155e72283, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624729, encodeId=89391624e2933, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2014-11-23 docwu2019
  4. [GetPortalCommentsPageByObjectIdResponse(id=1299836, encodeId=bd631299836e1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469069, encodeId=93841469069a0, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506196, encodeId=124515061965b, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3491, encryptionId=f8ec34917a, topicName=BiTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557722, encodeId=2be1155e72283, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624729, encodeId=89391624e2933, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2014-11-23 yangshch
  5. [GetPortalCommentsPageByObjectIdResponse(id=1299836, encodeId=bd631299836e1, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469069, encodeId=93841469069a0, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506196, encodeId=124515061965b, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3491, encryptionId=f8ec34917a, topicName=BiTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557722, encodeId=2be1155e72283, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624729, encodeId=89391624e2933, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2014-11-23 yaanren

相关资讯

战胜癌症:光靠重磅药物可不行

美国尼克松总统于1971年宣布了“癌症战争”的到来,然而四十多年后的今天,我们正在输掉这场战争。据美国癌症协会报道,2014年美国将诊断出167万的新癌症病例。今年,将有58.6万的美国人死于癌症,而整个世界范围内将有600万人死于癌症。尽管通过加大癌症治疗和预防上的投资,美国的癌症死亡率降到了85%以下,但是这与1975年比只下降了8%。这也许会让我们对目前采取的应对癌症的策略产生怀疑。爱因斯坦

Arrowhead公布RNAi药物ARC-520治疗乙肝临床二期研究数据

总部位于加利福尼亚州帕萨迪纳市的Arrowhead是一家专注于RNAi药物疗法开发的生物医药公司。最近其宣布开发的用于治疗乙肝的RNAi药物ARC-520取得良好的临床二期研究数据。 在这项有54名患者参与的临床二期研究中,研究数据显示,使用这种药物后,患者的乙肝表面抗原HbsAg明显减少。这也是目前第一种处于此阶段的RNAi药物。ARC-520采用了Arrowhead公司独有的Dynami

天伟院士:生物制药已成创新药物重要来源

日前,中国工程院院士、北京化工大学校长谭天伟在第十八届北京国际生物医药产业发展论坛上指出:虽然目前生物制药占的比例不是特别高,但其已经成为创新药物的重要来源。从国际市场来看,生物制药有很大的市场,应加快相关产业的发展。 论坛上,谭天伟作了题为《生物产业未来五年战略发展》的报告,该报告涉及生物医药、生物医学工程、生物制造和生物农业四个领域。 2013年,中国生物医药制造业和医疗器械产值达到2

勃林格殷格翰联手WellPoint开发新型心房颤动药物

长期以来,生物医药公司在进行相关药物研发时主要都专注于对疾病的疗效和副作用等方面。这也导致了许多药物在研发之初就未能考虑到患者和市场多种多样的需求。因此,许多药物在最终上市后的表现并未如预计的那样出色也就在预料之中了。 有鉴于此,制药巨头勃林格殷格翰公司最近宣布将与保健巨头WellPoint公司开展关于其正在研发的治疗心房颤动药物Pradaxa的临床实效研究。不同于传统临床研究,此次开展的临

汤森路透发布2014年10月药物快讯

概要: nAChRa7 新型强效正向变构调节剂见报 FDA 批准奈妥匹坦/帕洛诺司琼复方药治疗 CINV 新型强效 CETP 抑制剂 BI-415756 治疗心血管疾病 传统中药提取化合物具有抗银屑病作用 新型选择性前列腺素 EP2 受体激动剂在临床前研究中展现前景 Ripasudil 盐酸水合物在日本获得制造经销批准 FDA 批准 Baxter 公司的 Obizur 治疗获得性

药物研发策略正在剧变,全球都在变!

药物发现一直是药物研发漫长价值链的核心部分之一。然而,最近几年,由于受到全球金融危机和“重磅炸弹”药物专利到期的压力,几乎所有制药公司都在专注于后期阶段候选药物的开发。 但是,现在许多公司又认识到,他们早期的管道已经变得越来越薄弱。因此,早期药物的发现研究最近重新成为这些公司经营的关键点。不过,他们在这一领域的研究策略已经发生显着改变。 药物研发新策略 全球制药行业新的研发策略在不断演变